Pharmsintez's RAS loss for 3 months of 2023 was ₽47.345 million, down 37.1% from ₽75.26 million in the previous year. Revenue rose 32.9% to ₽63.474 million versus ₽47.75 million a year earlier.
Warning BlackTerminal uses cookies in order to personalize and improve the usability of the service. If you do not want to use cookies, please change your browser settings. Accept